Best GLP-1 for Type 2 Diabetes

Ranked Overview

The following rankings consider three key factors for type 2 diabetes management: A1C reduction, cardiovascular benefit, and weight loss. Rankings are based on clinical trial data and should be interpreted as a general reference. Individual treatment decisions should be made with a qualified healthcare provider based on a patient's specific clinical profile, comorbidities, and preferences.

#1: Mounjaro (Tirzepatide)

Mounjaro (tirzepatide, manufactured by Eli Lilly) is a dual GIP/GLP-1 receptor agonist administered once weekly via subcutaneous injection.

A1C reduction: In the SURPASS clinical trial program, tirzepatide demonstrated A1C reductions of up to 2.4% at the highest dose (15 mg), among the largest reductions observed with any non-insulin diabetes medication. In SURPASS-2, tirzepatide at all three doses (5 mg, 10 mg, 15 mg) showed statistically superior A1C reduction compared to semaglutide 1 mg.

Weight loss: Participants in SURPASS trials experienced average weight loss of up to 22.5 lbs (approximately 12-13% of body weight) at the highest dose, substantially more than with other GLP-1 RAs in their respective trials.

Cardiovascular data: As of this writing, the dedicated cardiovascular outcomes trial for tirzepatide in type 2 diabetes (SURPASS-CVOT) is ongoing. Tirzepatide does not yet have a labeled cardiovascular benefit indication for diabetes, which is one consideration when comparing it to medications with established CV outcomes data.

Dosing: Available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses. Patients typically start at 2.5 mg and titrate upward.

#2: Ozempic (Semaglutide)

Ozempic (semaglutide, manufactured by Novo Nordisk) is a GLP-1 receptor agonist administered once weekly via subcutaneous injection. An oral formulation (Rybelsus) is also available.

A1C reduction: In the SUSTAIN clinical trial program, semaglutide achieved A1C reductions of up to 1.8% at the 1 mg dose. The 2 mg dose, approved later, demonstrated A1C reductions of up to 2.0%.

Weight loss: Participants in SUSTAIN trials experienced average weight loss of approximately 10-14 lbs (roughly 5-6% of body weight), a meaningful secondary benefit for patients managing both diabetes and excess weight.

Cardiovascular benefit: In SUSTAIN 6, semaglutide demonstrated a 26% reduction in major adverse cardiovascular events (MACE) -- a composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke. This finding led to a cardiovascular benefit being included in the prescribing label, making Ozempic one of the few diabetes medications with demonstrated CV protection.

Dosing: Available in 0.25 mg (initiation dose), 0.5 mg, 1 mg, and 2 mg doses.

#3: Trulicity (Dulaglutide)

Trulicity (dulaglutide, manufactured by Eli Lilly) is a GLP-1 receptor agonist administered once weekly via a pre-filled auto-injector pen.

A1C reduction: In the AWARD clinical trial program, dulaglutide achieved A1C reductions of up to 1.5% at the 1.5 mg dose and up to 1.8% at the 4.5 mg dose.

Weight loss: Weight loss with dulaglutide was more modest compared to tirzepatide and semaglutide, with average reductions of approximately 6-10 lbs in clinical trials.

Cardiovascular benefit: The REWIND trial demonstrated a 12% reduction in MACE with dulaglutide compared to placebo. Notably, REWIND enrolled a broader population than many CV outcomes trials, including patients with cardiovascular risk factors but without established cardiovascular disease. This makes REWIND's findings particularly relevant for a wider range of type 2 diabetes patients.

Long track record: Trulicity was approved in 2014 and has an extensive real-world safety record. Its auto-injector pen design is considered straightforward by many patients and clinicians.

Dosing: Available in 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg doses.

Other Notable GLP-1 RAs for Diabetes

• Victoza (liraglutide): Daily injection with demonstrated cardiovascular benefit in the LEADER trial. Generally produces more modest A1C and weight reductions compared to the medications ranked above.
• Rybelsus (oral semaglutide): The only oral GLP-1 RA, studied in the PIONEER trial program. May be preferred by patients who wish to avoid injections, though A1C reduction is generally somewhat lower than injectable semaglutide.
• Byetta/Bydureon (exenatide): Among the earliest GLP-1 RAs, with established safety data but generally less A1C reduction and weight loss compared to newer agents.

Important Caveats

• Cross-trial limitations: Direct comparison of results from different trials is unreliable due to differences in patient populations, baseline A1C, concomitant medications, and trial duration. The SURPASS-2 head-to-head trial provides the most reliable comparison between tirzepatide and semaglutide.
• Cardiovascular outcomes: While Mounjaro demonstrates the strongest A1C reduction, it does not yet have dedicated cardiovascular outcomes data in diabetes. For patients with established cardiovascular disease, the proven CV benefits of Ozempic or Trulicity may weigh heavily in treatment selection.
• Individual variation: A1C reductions and weight loss outcomes vary among individuals. Factors such as baseline A1C, duration of diabetes, kidney function, and adherence all influence results.
• Side effects: Gastrointestinal side effects (nausea, vomiting, diarrhea) are common across all GLP-1 RAs, particularly during dose titration. Most patients experience improvement over time.
• Cost and access: Insurance coverage, prior authorization requirements, and out-of-pocket costs vary significantly and may influence which medication is most practical.

This content is for informational purposes only and does not constitute medical advice. Treatment decisions for type 2 diabetes should be made in consultation with a qualified healthcare provider who can evaluate the full clinical picture.